Volume | 2,857,186 |
|
|||||
News | - | ||||||
Day High | 142.91 | Low High |
|||||
Day Low | 141.14 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Novo Nordisk | NVO | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
142.78 | 141.14 | 142.91 | 142.49 | 143.26 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
50,284 | 2,857,186 | US$ 141.88 | US$ 405,388,778 | - | 75.56 - 144.50 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:59:56 | 1 | US$ 142.24 | USD |
Novo Nordisk (NVO) Options Flow Summary
Novo Nordisk Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
644.61B | 4.51B | - | 232.26B | 83.68B | 18.56 | 7.70 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Novo Nordisk News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NVO Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 141.19 | 144.50 | 140.8901 | 142.73 | 3,840,769 | 1.21 | 0.86% |
1 Month | 133.15 | 144.50 | 130.85 | 137.54 | 3,492,581 | 9.25 | 6.95% |
3 Months | 129.00 | 144.50 | 121.2902 | 130.11 | 3,811,414 | 13.40 | 10.39% |
6 Months | 96.98 | 144.50 | 96.53 | 122.35 | 4,481,275 | 45.42 | 46.83% |
1 Year | 79.60 | 144.50 | 75.56 | 111.14 | 3,771,837 | 62.80 | 78.89% |
3 Years | 42.02 | 144.50 | 40.825 | 89.30 | 2,152,160 | 100.38 | 238.89% |
5 Years | 26.22 | 144.50 | 23.575 | 71.92 | 1,833,799 | 116.18 | 443.10% |
Novo Nordisk Description
Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders. |